Gilead Sciences, Inc. (GILD) Position Held by Empirical Financial Services LLC
Empirical Financial Services LLC maintained its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,248 shares of the biopharmaceutical company’s stock at the end of the second quarter. Empirical Financial Services LLC’s holdings in Gilead Sciences were worth $301,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC increased its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. American Beacon Advisors Inc. bought a new position in shares of Gilead Sciences in the first quarter worth about $143,000. Sterling Investment Advisors Ltd. bought a new position in shares of Gilead Sciences in the second quarter worth about $184,000. Finally, Washington Trust Bank increased its stake in shares of Gilead Sciences by 24.8% in the second quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 550 shares during the period. Institutional investors own 74.62% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.85 on Tuesday. The firm has a market cap of $96,363.46, a price-to-earnings ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.75 EPS. analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.69%.
GILD has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a research note on Monday, July 17th. BMO Capital Markets reiterated a “hold” rating and issued a $72.00 price objective on shares of Gilead Sciences in a research note on Friday, July 21st. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Leerink Swann restated a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 25th. Finally, Robert W. Baird restated an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $84.87.
In related news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $83.11, for a total value of $6,094,705.63. Following the completion of the transaction, the insider now directly owns 2,996,766 shares of the company’s stock, valued at approximately $249,061,222.26. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 446,819 shares of company stock valued at $36,269,486. Company insiders own 1.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/14/gilead-sciences-inc-gild-position-held-by-empirical-financial-services-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.